News

March 3, 2021March 3, 2021

Pivotal Phase 3 Trials of Oral Simufilam Planned for Year’s End

News

Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease, in the second half of this year, ... Read more

March 1, 2021March 1, 2021

Phase 1 Trial to Test BDNF Gene Therapy in Alzheimer’s Patients

News

A Phase 1 trial will evaluate the use of gene therapy in delivering brain-derived neurotrophic factor (BDNF) to the brains of people with Alzheimer’s disease or mild cognitive impairment ... Read more

February 24, 2021February 24, 2021

Grants of $4.6M to Support Trials of Cancer Therapy in Early Alzheimer’s

News

The National Institute of Aging (NIA) and the Alzheimer’s Drug Discovery Foundation (ADDF) have awarded $4.6 million to a team of researchers studying the potential of the cancer therapy ... Read more

February 22, 2021February 22, 2021

UsAgainstAlzheimer’s Calls for $289M Hike in Federal Funds for Research

News

To meet a U.S. goal to effectively treat and prevent Alzheimer’s disease by 2025, patient, caregiver, and advocacy communities are recommending a $289 million hike in federal research dollars ... Read more

February 17, 2021February 17, 2021

HFC to Host CareCon, Virtual Event for Caregivers

News

A virtual celebrity-studded HFC event aimed at caregivers for Alzheimer’s disease and dementia patients is on tap for Friday, National Caregivers Day. Called HFC CareCon and presented by Kensington Senior ... Read more

February 15, 2021February 15, 2021

Oral Simufilam Found to Improve Cognition, Behavior After 6 Months’ Use

News

Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim ... Read more

February 10, 2021February 10, 2021

Alzheimer’s Association Webinar Tackles Care Disparities for Blacks in US

News

Older Blacks in the U.S. are twice as likely to develop Alzheimer’s disease (AD) as whites of a similar age, and they’re less likely to be diagnosed. Such a ... Read more

February 8, 2021February 9, 2021

Adira Foundation Arises From Life-altering Accident to Help Those With Chronic Ills

News, syndicated

Note: This story was updated Feb. 9, 2021, to clarify details surrounding the grant Chronic Care Collaborative received from Adira. Greg Smiley’s world changed abruptly in 2013. He was ... Read more

February 8, 2021February 8, 2021

Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

News

NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug ... Read more

February 3, 2021February 3, 2021

Troriluzole Fails to Ease Cognitive Impairments in Phase 2/3 Trial

News

Troriluzole, an investigational oral symptomatic treatment developed by Biohaven for Alzheimer’s disease, did not work better than a placebo in alleviating cognitive impairments and reducing brain volume loss in ... Read more